Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 5, 2008, Pages 556-567

  Hamadani, Mehdi ^a   Awan, Farrukh T ^a   Copelan, Edward A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Acute leukemia; Acute myeloid leukemia; Bone marrow transplantation; Graft versus leukemia effect; Hematopoietic stem cell transplantation; Reduced intensity

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IDARUBICIN; MELPHALAN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; STEM CELL FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COMORBIDITY; CORD BLOOD STEM CELL TRANSPLANTATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA TYPING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MYELOABLATIVE CONDITIONING; NONHUMAN; POINT MUTATION; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RISK FACTOR; TREATMENT OUTCOME; TUMOR IMMUNITY; WHOLE BODY RADIATION;

GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; PRACTICE GUIDELINES AS TOPIC; TRANSPLANTATION CONDITIONING;

EID: 41949142667     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.019     Document Type: Article

References (104)

1. Gratwohl A., Baldomero H., Frauendorfer K., et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 39 (2007) 71-87
2. Mannick J.A., Lochete Jr. H.L., Ashley C.A., et al. Autografts of bone marrow in dogs after lethal total-body radiation. Blood 15 (1960) 255-266
3. Lorenz E., Uphoff D., Reid T.R., et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 12 (1951) 197-201
4. Storb R., Epstein R.B., Graham T.C., et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9 (1970) 240-246
5. Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49 (1977) 511-533
6. Thomas E.D., Buckner C.D., Clift R.A., et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301 (1979) 597-599
7. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
8. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-658
9. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 5 (2005) 275-284
10. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
11. Bonnet D., Warren E.H., Greenberg P.D., et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 96 (1999) 8639-8644
12. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 354 (2006) 1813-1826
13. Pearce D.J., Taussig D., Zibara K., et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107 (2006) 1166-1173
14. Creutzig U., Ritter J., Zimmermann M., et al. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 103 (1998) 100-109
15. Buchner T., Urbanitz D., Hiddemann W., et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3 (1985) 1583-1589
16. Geller R.B. Post-remission therapy of acute myelocytic leukemia in adults: curability breeds controversy. Leukemia 6 (1992) 915-925
17. Champlin R.E., Ho W.G., Gale R.P., et al. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 102 (1985) 285-291
18. Appelbaum F.R., Dahlberg S., Thomas E.D., et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 101 (1984) 581-588
19. Archimbaud E., Thomas X., Michallet M., et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 12 (1994) 262-267
20. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (1995) 217-223
21. Burnett A.K., Goldstone A.H., Stevens R.M., et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351 (1998) 700-708
22. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
23. Harousseau J.L., Cahn J.Y., Pignon B., et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 90 (1997) 2978-2986
24. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102 (2003) 1232-1240
25. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
26. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
27. Levi I., Grotto I., Yerushalmi R., et al. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Res 28 (2004) 605-612
28. Nathan P., Sung L., Crump M., and Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 96 (2004) 38-45
29. Tallman M.S., Kopecky K.J., Amos D., et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 7 (1989) 326-337
30. Appelbaum F.R., and Pearce S.F. Hematopoietic cell transplantation in first complete remission versus early relapse. Best Pract Res Clin Haematol 19 (2006) 333-339
31. Armand P., Kim H.T., DeAngelo D.J., et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13 (2007) 655-664
32. Chang C., Storer B.E., Scott B.L., et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110 (2007) 1379-1387
33. Smith S.M., Le Beau M.M., Huo D., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102 (2003) 43-52
34. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (1998) 4173-4179
35. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
36. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083
37. Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103 (2005) 1652-1658
38. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
39. Dohner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20 (2002) 3254-3261
40. Baldus C.D., Tanner S.M., Kusewitt D.F., et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol 31 (2003) 1051-1056
41. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 (2005) 254-266
42. Preudhomme C., Sagot C., Boissel N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100 (2002) 2717-2723
43. Schlenk R., Corbacioglu A., Krauter J., et al. Gene mutations as predicitive markers for postremission therapy in younger adults with normal karyotype AML. Blood 108 (2006) 4
44. Drobyski W.R. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 18 (2004) 1565-1568
45. Anasetti C., Perkins J., Nieder M.L., et al. Are matched unrelated donor transplants justified for AML in CR1?. Best Pract Res Clin Haematol 19 (2006) 321-328
46. Cornelissen J.J., and Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2005) 151-155
47. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 (2006) 5695-5702
48. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 (2007) 3108-3114
49. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
50. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26 (2000) 397-404
51. Tallman M., Dewald G., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first of second complete remission. Blood 110 (2007) 409-417
52. Krauter J., Heil G., Hoelzer D., et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood (2005) 106:Abstract 172
53. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339 (1998) 1565-1577
54. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
55. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
56. Hwang W.Y., Samuel M., Tan D., et al. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 13 (2007) 444-453
57. Takahashi S., Ooi J., Tomonari A., et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 109 (2007) 1322-1330
58. Brunstein C.G., Barker J.N., McGlave P.B., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110 (2007) 3064-3070
59. Sekeres M.A., Stone R.M., Zahrieh D., et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18 (2004) 809-816
60. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
61. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood (2007)
62. Giles F.J., Borthakur G., Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136 (2007) 624-627
63. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
64. Song K.W., and Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant 36 (2005) 183-191
65. Biggs J.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80 (1992) 1090-1093
66. Michallet M., Thomas X., Vernant J.P., et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 26 (2000) 1157-1163
67. Fung H.C., Stein A., Slovak M., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9 (2003) 766-771
68. Esteve J., Labopin M., Finke J., et al. Allogeneic stem-cell transplantation for patients with de novo acute myeloid leukemia not in complete response: results of a survey from the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood 104 (2004) 633a
69. Wong R., Shahjahan M., Wang X., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11 (2005) 108-114
70. Breems D.A., Van Putten W.L., Huijgens P.C., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23 (2005) 1969-1978
71. Gale R.P., Horowitz M.M., Rees J.K., et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10 (1996) 13-19
72. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10 (1992) 1723-1729
73. Brown R.A., Wolff S.N., Fay J.W., et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 85 (1995) 1391-1395
74. Blum W., Bolwell B.J., Phillips G., et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 12 (2006) 61-67
75. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 35 (2005) 1011-1018
76. Linker C.A., Damon L.E., Ries C.A., et al. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 29 (2002) 297-301
77. Chantry A.D., Snowden J.A., Craddock C., et al. Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Biol Blood Marrow Transplant 12 (2006) 1310-1317
78. Gorin N.C., Labopin M., Meloni G., et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 5 (1991) 896-904
79. Burnett A.K., Hills R.K., Goldstone A.H., et al. The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML 10 and 12 Trials. Blood 104 (2004) Abstract 620
80. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
81. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
82. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
83. Rieg LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website 2007.
84. Niederwieser D., Lange T., Cross M., et al. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 19 (2006) 825-838
85. Kojima R., Kami M., Kanda Y., et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 36 (2005) 667-674
86. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12 (2006) 1047-1055
87. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activing mutation in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
88. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML 1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 (2006) 1791-1799
89. Gondek L., Tiu R., O'Keefe C., et al. Chromosomal lesion and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. Blood (2007 Oct 22) [Epub ahead of print]
90. Gal H., Amariglio N., Trakhtenbrt L., et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20 (2006) 2147-2154
91. Irish J.M., Hovland R., Krutzik P.O., et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118 (2004) 217-218
92. Blair A., Hogge D.E., Ailles L.E., et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in-vitro and in-vivo. Blood 89 (1997) 3104-3112
93. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105 (2005) 4163-4169
94. Jin L., Hope K.J., Zhai Q., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006) 1167-1174
95. Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118 (2002) 385-400
96. Sayer H.G., Kroger M., Beyer J., et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31 (2003) 1089-1095
97. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
98. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
99. van Besien K., Artz A., Smith S., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23 (2005) 5728-5738
100. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393
101. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
102. Bertz H., Potthoff K., and Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21 (2003) 1480-1484
103. Ringhoffer M., Blumstein N., Neumaier B., et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 130 (2005) 604-613
104. Gupta V., Daly A., Lipton J.H., et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11 (2005) 764-772